Literature DB >> 9930876

PCR-mediated recombination: a general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA.

G Fang1, B Weiser, A Visosky, T Moran, H Burger.   

Abstract

A PCR-based approach was developed that provides a powerful tool for engineering recombinant molecules without reliance on restriction sites. DNA sequences were first amplified by high-fidelity PCR using Pfu polymerase; they were then used both as 'megaprimers' and templates in subsequent asymmetric long PCR amplifications to form chimeric clones. To demonstrate the technique, we constructed chimeric full-length HIV-1 clones derived from reverse-transcribed plasma viral RNA and proviral LTRs. Biologic characterization of these clones showed that most were infectious in tissue culture and sequence analysis demonstrated an error rate of only one base change in 20 kb of DNA sequence. For PCR-mediated recombination, it is necessary to know the sequence of the 3' and 5' overlapping regions of the desired PCR products. This method may be extended to include construction of chimeras between any DNA fragments lacking sequence homology. Such chimeras may be constructed by introducing overlapping sequences to one of the fragments. To ensure that unwanted mutations have not been introduced into the clones constructed by this method, each clone should be sequenced. Our results demonstrate that by using a high-fidelity polymerase and highly controlled PCR conditions, the PCR-introduced error rate can be greatly minimized. This new procedure may be used to construct infectious chimeras of HIV or SIV for studies of vaccines and pathogenesis. Moreover, the method is designed to exchange viral genes at precise boundaries to study individual gene products from different HIV genomes. It can also be used to construct expression vectors for production of specific proteins or delivery vectors for gene transfer and gene therapy. Finally, the technique described here provides a versatile tool to transfer genes or gene fragments from different sources for genetic investigation and engineering.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9930876     DOI: 10.1038/5607

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  21 in total

1.  Structural requirements of bitter taste receptor activation.

Authors:  Anne Brockhoff; Maik Behrens; Masha Y Niv; Wolfgang Meyerhof
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

3.  Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.

Authors:  Kazuhiko Ide; Manabu Aoki; Masayuki Amano; Yasuhiro Koh; Ravikiran S Yedidi; Debananda Das; Sofiya Leschenko; Bruno Chapsal; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.

Authors:  Yasuhiro Koh; Manabu Aoki; Matthew L Danish; Hiromi Aoki-Ogata; Masayuki Amano; Debananda Das; Robert W Shafer; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

5.  Rapid and efficient gene splicing using megaprimer-based protocol.

Authors:  Ji-Ren Chen; Jing-Jing Lü; Hua-Fang Wang
Journal:  Mol Biotechnol       Date:  2008-06-24       Impact factor: 2.695

6.  The transmembrane domain of the molecular chaperone Cosmc directs its localization to the endoplasmic reticulum.

Authors:  Qian Sun; Tongzhong Ju; Richard D Cummings
Journal:  J Biol Chem       Date:  2011-01-24       Impact factor: 5.157

7.  Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

Authors:  Yasushi Tojo; Yasuhiro Koh; Masayuki Amano; Manabu Aoki; Debananda Das; Sarang Kulkarni; David D Anderson; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

8.  Development and validation of a cell-based assay system to assess human immunodeficiency virus type 1 integrase multimerization.

Authors:  Tomofumi Nakamura; Joseph R Campbell; Amber R Moore; Sachiko Otsu; Haruo Aikawa; Hirokazu Tamamura; Hiroaki Mitsuya
Journal:  J Virol Methods       Date:  2016-07-26       Impact factor: 2.014

9.  Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees.

Authors:  Jun Takehisa; Matthias H Kraus; Julie M Decker; Yingying Li; Brandon F Keele; Fréderic Bibollet-Ruche; Kenneth P Zammit; Zhiping Weng; Mario L Santiago; Shadrack Kamenya; Michael L Wilson; Anne E Pusey; Elizabeth Bailes; Paul M Sharp; George M Shaw; Beatrice H Hahn
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

10.  Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.

Authors:  Sadahiro Tamiya; Sek Mardy; Mark F Kavlick; Kazuhisa Yoshimura; Hiroaki Mistuya
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.